The new facility, in the Research Triangle Park area of North Carolina, will support the company’s companion diagnostic (CDx) development partnerships and the downstream delivery of assays for patient testing.
"Almac Diagnostics have been experiencing rapid growth and increased client demand for our companion diagnostic development services, therefore the additional facility will offer increased capacity in order to meet the increasing customer demand and to support our future growing client base," Professor Paul Harkin, President and Managing Director of Almac Diagnostics told Outsourcing-Pharma.com.
"In addition, the US-based facility will provide enhanced support to our US customers for US-based clinical trial testing from Almac’s global CLIA laboratories," added Harkin.
The 150,000-square-foot facility features molecular biology laboratories with microarray and quantitative Polymerase Chain Reaction (qPCR) platforms for companion diagnostic development and, according to the company, will operate both research-use-only and clinical diagnostic tests.
The company also plans to add additional technology platforms including NGS within the next year.